ストックスクリーナーアプリを入手
113.08
1.37%
1.5245
前日終値:
$111.56
開ける：
$112.8
24時間の取引高:
5,819
Relative Volume:
0.05
時価総額：
$2.10B
収益：
$118.31M
当期純損益:
$96.34M
株価収益率:
78.53
EPS:
1.44
ネットキャッシュフロー:
$-19.62M
1週間 パフォーマンス:
-2.05%
1か月 パフォーマンス:
+5.90%
6か月 パフォーマンス:
+29.98%
1年 パフォーマンス:
+93.37%
1日の値動き範囲:
$112.06
$114.14
1週間の範囲:
$109.44
$116.52
52週間の値動き範囲:
$57.00
$129.90
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
名前
Ligand Pharmaceuticals Inc
セクター
電話
858-550-7500
住所
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
LGND を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| LGND | 112.16 | 2.10B | 118.31M | 96.34M | -19.62M | 1.44 |
| VRTX | 447.51 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.90 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.12 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.56 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-04-14 | 再開されました | Stephens | Overweight |
| 2021-02-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-10-06 | 開始されました | Barclays | Overweight |
| 2020-03-24 | ダウングレード | Argus | Buy → Hold |
| 2020-03-10 | 開始されました | Guggenheim | Neutral |
| 2020-02-06 | 開始されました | The Benchmark Company | Buy |
| 2019-09-19 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-06-11 | 開始されました | Barclays | Equal Weight |
| 2019-05-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-10-29 | アップグレード | ROTH Capital | Neutral → Buy |
| 2018-10-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-11 | 繰り返されました | Argus | Buy |
| 2018-08-17 | 開始されました | Goldman | Neutral |
| 2018-08-08 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2018-06-21 | 開始されました | Argus | Buy |
| 2017-12-27 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-09-05 | 再開されました | H.C. Wainwright | Buy |
| 2016-10-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2016-08-05 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2016-03-11 | 開始されました | Sidoti | Buy |
| 2016-03-03 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Ligand Pharmaceuticals Inc (LGND) 最新ニュース
Royce & Associates LP Sells 4,996 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Should Be Cautious Despite Solid Earnings - Yahoo Finance
Janus Henderson Group PLC Expands Stake in Ligand Pharmaceuticals Inc - GuruFocus.com
Ligand Pharmaceuticals to Present at Stifel 2024 Healthcare Conference | LGND Stock News - StockTitan
Royal Bank of Canada Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Given New $150.00 Price Target at Barclays - Defense World
Ligand Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com Canada
LGND: 3Q Sales Surprise to the Upside - Zacks Small Cap Research
Lisanti Capital Growth LLC Makes New Investment in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Stock Price Expected to Rise, Benchmark Analyst Says - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Shares Down 7.7%Should You Sell? - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2024 Earnings Call Transcript - Insider Monkey
Ligand Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Villere ST Denis J & Co. LLC Lowers Stake in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast - Investing.com India
Earnings call: Ligand reports robust Q3 growth, raises 2024 forecast By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $150.00 at Barclays - MarketBeat
Oppenheimer Forecasts Strong Price Appreciation for Ligand Pharmaceuticals (NASDAQ:LGND) Stock - MarketBeat
A Closer Look at 7 Analyst Recommendations For Ligand Pharmaceuticals - Benzinga
Ligand Pharmaceuticals (NASDAQ:LGND) Given Buy Rating at HC Wainwright - MarketBeat
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price - Yahoo Finance
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highligh - GuruFocus.com
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Ligand Pharmaceuticals Reports Strong Q3 2024 Growth - TipRanks
Ligand: Q3 Earnings Snapshot - Houston Chronicle
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance - BioSpace
Ligand Pharmaceuticals (NASDAQ:LGND) Releases FY24 Earnings Guidance - MarketBeat
Ligand Pharmaceuticals Q3 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Ligand Pharmaceuticals stock hits 52-week high at $116.25 - Investing.com
Ligand Pharmaceuticals stock hits 52-week high at $116.25 By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need T - GuruFocus.com
Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
H.C. Wainwright reiterated coverage on Viking Therapeutics with a new price target - Quantisnow
Ligand Pharmaceuticals (NASDAQ:LGND) Earns Buy Rating from HC Wainwright - Defense World
Macquarie Group Ltd's Strategic Reduction in Ligand Pharmaceuticals Inc - GuruFocus.com
Ligand Pharmaceuticals (STU:LGDN) Preferred Stock : €0.0 Mil (As of Jun. 2024) - GuruFocus.com
Ligand Pharmaceuticals (FRA:LGDN) Momentum Rank : 6 (As of Nov. 01, 2024) - GuruFocus.com
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston - StockTitan
Stephens Investment Management Group LLC Sells 33,304 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Market Participants Recognise Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Earnings - Simply Wall St
Congress Asset Management Co. Has $60.46 Million Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - MarketBeat
Ligand Pharmaceuticals' (LGND) Buy Rating Reiterated at HC Wainwright - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $125.00 - MarketBeat
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Position Raised by Allspring Global Investments Holdings LLC - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month HighTime to Buy? - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $112.25 - Investing.com
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 - Marketscreener.com
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 | LGND Stock News - StockTitan
Ligand Pharmaceuticals (NASDAQ:LGND) PT Raised to $157.00 at HC Wainwright - Defense World
Critical Insights From Ligand Pharmaceuticals Analyst Ratings: What You Need To Know - Benzinga
Ligand Pharmaceuticals Inc (LGND) 財務データ
収益
当期純利益
現金流量
EPS
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):